Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Jaguar Health Inc
(NQ:
JAGX
)
3.780
-0.270 (-6.67%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Jaguar Health Inc
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
20 Stocks Moving in Thursday's Pre-Market Session
January 13, 2022
Gainers BTCS Inc. (NASDAQ: BTCS) rose 41% to $9.45 in pre-market trading after jumping 19% on Wednesday. Adagio Therapeutics, Inc. (NASDAQ: ADGI) rose 22.8% to $7.16 in pre-...
Via
Benzinga
50 Biggest Movers From Yesterday
January 13, 2022
Gainers electroCore, Inc. (NASDAQ: ECOR) shares jumped 64% to settle at $0.88 on Wednesday after the company's gammaCore nVNS device received FDA Breakthrough Designation for...
Via
Benzinga
Why Jaguar Health Shares Are Rising
January 12, 2022
Jaguar Health Inc (NASDAQ:JAGX) shares are trading higher ...
Via
Benzinga
28 Stocks Moving In Wednesday's Mid-Day Session
January 12, 2022
Gainers Immuron Limited (NASDAQ: IMRN) shares jumped 40.2% to $3.5887. Immuron received funding of A$6.2 ($4.45) million from the U.S Department of Defense to examine a dosing...
Via
Benzinga
NIO Stock Alert: The Steel Deal That Has EV Maker Nio Driving Higher
January 12, 2022
Nio (NIO) stock is rising higher on Wednesday following news of a deal with Baoshan Iron & Steel and we've got all the details!
Via
InvestorPlace
Chinese Tech Stocks: Why Are DIDI, JD and BABA Moving Higher Today?
January 12, 2022
Chinese tech stocks are on the move Wednesday and we're diving into the latest news that has these shares heading higher today!
Via
InvestorPlace
JAGX Stock Alert: What Is Going on With Jaguar Health Today?
January 12, 2022
JAGX stock is rallying on Wednesday after a rough year thanks to news that Oasis Capital has taken a 10% stake in Jaguar Health.
Via
InvestorPlace
Jaguar Animal Health to Host Treatment Forum for Veterinarians About Chemotherapy-Induced Diarrhea (CID) in Dogs on Sunday, January 16th During the Veterinary Meeting & Expo (VMX) Conference in Orlando, Florida
January 12, 2022
Canalevia™-CA1, which received conditional approval from the FDA on December 21, 2021, is the first and only treatment for CID in dogs to receive any type of approval from FDA U.S. veterinarians,...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
January 12, 2022
Gainers Immuron (NASDAQ:IMRN) stock moved upwards by 69.5% to $4.44 during Wednesday's pre-market session. The market value of their outstanding shares is at $25.2...
Via
Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
January 12, 2022
Good morning, trader! Let's get this party started with a dive into the biggest pre-market stock movers to watch for Wednesday!
Via
InvestorPlace
15 Stocks Moving in Wednesday's Pre-Market Session
January 12, 2022
Gainers Kidpik Corp. (NASDAQ: PIK) rose 34.4% to $8.13 in pre-market trading after jumping more than 27% on Tuesday. Kidpik, last month, posted a Q3 loss of $0.22 per share....
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
January 11, 2022
Gainers Jaguar Health (NASDAQ:JAGX) stock...
Via
Benzinga
Jaguar Health Launches Canalevia-CA1 (Crofelemer) for the Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs
January 04, 2022
The Canalevia.com website, a resource for veterinarians and dog owners, is now live Canalevia™-CA1 is the first and only treatment for chemotherapy-induced diarrhea (CID) in dogs to receive any type of...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
12 Health Care Stocks Moving In Wednesday's Intraday Session
December 22, 2021
Gainers BiondVax Pharmaceuticals (NASDAQ:BVXV...
Via
Benzinga
Jaguar Health Shares Comments from FDA’s December 21 Press Release About Conditional Approval of Canalevia-CA1 (Crofelemer) for Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs
December 22, 2021
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
FDA Approves Jaguar Health's Plant-Based Therapy For Chemo-Induced Diarrhea In Dogs
December 22, 2021
The FDA has granted conditional approval for Jaguar Health Inc's (NASDAQ: JAGX) Canalevia-CA1 (crofelemer delayed-release tablets) for chemotherapy-induced...
Via
Benzinga
12 Health Care Stocks Moving In Tuesday's After-Market Session
December 21, 2021
Gainers BioRestorative Therapies (NASDAQ:BRTX...
Via
Benzinga
JAGX Stock Alert: 5 Things to Know About the News Sending Jaguar Health Higher
December 21, 2021
Shares of JAGX stock are flying higher after the FDA granted conditional approval for its chemotherapy-induced diarrhea treatment.
Via
InvestorPlace
Jaguar Health Announces FDA Conditional Approval of Canalevia-CA1 (Crofelemer), the First and Only Treatment for Chemotherapy-Induced Diarrhea (CID) in Dogs to Receive Any Type of Approval from FDA
December 21, 2021
By prescription only, Canalevia™-CA1 is a canine-specific formulation of crofelemer, Jaguar's novel, oral plant-based product sustainably harvested from the Croton lechleri tree SAN FRANCISCO, CA /...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
12 Health Care Stocks Moving In Tuesday's Intraday Session
December 21, 2021
Gainers Jaguar Health (NASDAQ:JAGX) shares increased by 58.26% to $1.82 during Tuesday's regular session. Trading volume for this security as of 12:30 EST is 28.4...
Via
Benzinga
Jaguar Health’s Subsidiary Napo EU Changes Name to Napo Therapeutics, Reflecting the Italian Company’s Focus on Rare Diseases & Orphan Drugs
December 20, 2021
SAN FRANCISCO, CA / ACCESSWIRE / December 20, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced that the name of its majority owned subsidiary changed from Napo EU S.p.A. to Napo Therapeutics...
From
Jaguar Health, Inc.
Via
AccessWire
European Medicines Agency Grants Orphan Drug Designation for Crofelemer to Napo EU, Jaguar Health’s Italian Subsidiary, for Short Bowel Syndrome
December 13, 2021
The recognition of Orphan Drug Designation in Europe for crofelemer for this rare disease is the first key milestone of Napo EU under the company's exclusive license agreement with Jaguar Health SAN...
From
Jaguar Health, Inc.
Via
AccessWire
Jaguar Health Announces the Presentation of Findings from the Investigator-Initiated Phase 2 HALT-D Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients at San Antonio Breast Cancer Symposium (SABCS 2021)
December 10, 2021
Results of the study provide the first proof-of-concept data for potential use of crofelemer - a novel, oral, plant-based, non-opioid antidiarrheal prescription medication - in breast cancer patients...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
The Daily Biotech Pulse: Lilly Sings Metabolic Disorder Drug Pact, Moderna Reports Positive Flu Vaccine Data, Halozyme To Buy Back Shares
December 10, 2021
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Angion Biomedica's ANG-3777 Does Not Meet Primary Endpoint In Mid-Stage...
Via
Benzinga
12 Health Care Stocks Moving In Wednesday's After-Market Session
December 08, 2021
Gainers Aptinyx (NASDAQ:APTX) shares rose...
Via
Benzinga
Jaguar Health to Host Scientific Discussion about Cancer Therapy-Related Diarrhea in Breast Cancer and the Company’s Ongoing OnTarget Pivotal Phase 3 Trial at San Antonio Breast Cancer Symposium (SABCS 2021)
December 06, 2021
Content from the discussion will be featured in upcoming "Diarrhea Dialogues: Part 2" SAN FRANCISCO, CA / ACCESSWIRE / December 6, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced it is hosting...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Jaguar Health's Posts Crofelemer Data For Chemo-Induced Diarrhea In Breast Cancer Patients
November 19, 2021
Jaguar Health Inc (NASDAQ: JAGX) announced the topline results of the investigator-initiated Phase 2 HALT-D trial evaluating crofelemer to prevent chemotherapy-...
Via
Benzinga
The Week Ahead In Biotech (Dec. 6-Dec. 11): Daré FDA Decision, Adcom Tryst For Reata, Multiple Conference Presentations And More
December 06, 2021
The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative...
Via
Benzinga
Exposures
Product Safety
Jaguar Health Announces Topline Results of Investigator-Initiated Phase 2 Study of Crofelemer for Prevention of Chemotherapy-Induced Diarrhea (CID) in Breast Cancer Patients
November 19, 2021
Crofelemer is a novel, oral plant-based non-opioid antidiarrheal medication SAN FRANCISCO, CA / ACCESSWIRE / November 19, 2021 / Jaguar Health, Inc. (NASDAQ:JAGX) today announced topline results of the...
From
Jaguar Health, Inc.
Via
AccessWire
Exposures
Product Safety
Looking Into Jaguar Health's Return On Capital Employed
November 17, 2021
According to data from Benzinga Pro, during Q3, Jaguar Health's (NASDAQ:JAGX) reported sales totaled $630.00 thousand. Despite a 17.71% increase in earnings, the company posted a...
Via
Benzinga
< Previous
1
2
...
10
11
12
13
14
15
16
17
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.